#South Korea #Samsung Biologics #Incheon #ESG Management #Dow Jones Index

Samsung Biologics' Sustainability Recognition

Samsung Biologics has proudly announced its inclusion in the prestigious Dow Jones Best-in-Class World Index for the fifth consecutive year. This acknowledgment underscores their unwavering commitment to sustainable growth and responsible business practices, particularly as a leading contract development and manufacturing organization (CDMO).

The Dow Jones World Index, which was formerly known as the Dow Jones Sustainability Index, assesses the sustainability performance of over 2,500 companies worldwide based on the SP Global Corporate Sustainability Assessment (CSA). This rigorous evaluation considers various environmental, social, and governance (ESG) metrics, determining which companies rank at the top of their respective industries. Samsung Biologics has consistently showcased its dedication to improving performance through enhanced sustainability data disclosures and robust ESG management practices.

In recent assessments, Samsung Biologics achieved commendable results across several key focus areas, including supply chain management, workplace health and safety, and environmental stewardship. These advancements illustrate the company's effective integration of ESG considerations into its operational framework and business conduct.

John Rim, the President and CEO of Samsung Biologics, emphasized the importance of this recognition, stating, “This showcases our steady progress in strengthening the sustainability management framework throughout all areas of our business.” Moreover, Rim also plays a significant role as a champion within the Sustainable Markets Initiative (SMI), specifically in the Supply Chains Working Group. His leadership reflects the company’s ongoing commitment to transparency and responsible growth, aiming for long-term value creation for clients, communities, and stakeholders alike.

The consistent inclusion in the Dow Jones Index not only reflects Samsung Biologics’ strengths but also reveals the company's proactive responses to the evolving expectations from global investors and stakeholders. Over the past year, Samsung Biologics was awarded an EcoVadis Platinum rating, further solidifying its reputation for sustainability and excellence in social responsibility. They also received accolades at the CDMO Leadership Awards, enhancing their prestige within the industry.

Samsung Biologics operates from its state-of-the-art Bio Campuses I and II, boasting a combined biomanufacturing capacity of 785,000 liters and an additional 60,000 liters from their Maryland facility, leading to a total of 845,000 liters of manufacturing capacity worldwide. The firm is also paving the way for future growth by securing land for its third Bio Campus, indicating its readiness to accommodate next-generation therapies and evolving market demands.

With a global presence, Samsung Biologics supports clients across the U.S., Europe, and Asia Pacific, enhancing its delivery of diverse modalities such as multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. The company upholds its ExellenS™ framework, promoting standardized designs, streamlined processes, and advanced digitalization across its manufacturing network.

Through investments aimed at maximizing operational excellence, Samsung Biologics remains committed to providing high-quality biomedicines on time while making sustainable decisions for the betterment of society and global health. Such efforts showcase their determination to drive the biopharmaceutical sector towards a more sustainable future.

For more details, visit Samsung Biologics.